Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19

NCT05656443 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

1246

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Pneumonia

Interventions

DRUG: GST-HG171/Ritonavir
DRUG: Placebo

Sponsor

Fujian Akeylink Biotechnology Co., Ltd.